Pyxis Oncology FY2024 EPS Forecast Lowered by HC Wainwright

Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Investment analysts at HC Wainwright lowered their FY2024 earnings estimates for Pyxis Oncology in a research note issued on Wednesday, November 13th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($1.00) for the year, down from their prior estimate of ($0.89). HC Wainwright has a "Buy" rating and a $7.00 price objective on the stock. The consensus estimate for Pyxis Oncology's current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Pyxis Oncology's Q4 2024 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($1.46) EPS, FY2026 earnings at ($1.33) EPS, FY2027 earnings at ($1.44) EPS and FY2028 earnings at ($0.75) EPS.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.04.

Other equities analysts have also issued research reports about the stock. Royal Bank of Canada reiterated an "outperform" rating and issued a $7.00 price target on shares of Pyxis Oncology in a report on Thursday, September 19th. Stephens assumed coverage on shares of Pyxis Oncology in a research note on Friday, November 8th. They issued an "overweight" rating and a $13.00 target price on the stock. Finally, Stifel Nicolaus assumed coverage on shares of Pyxis Oncology in a research note on Thursday, August 8th. They issued a "buy" rating and a $10.00 target price on the stock. Eight analysts have rated the stock with a buy rating, According to MarketBeat, Pyxis Oncology currently has a consensus rating of "Buy" and a consensus price target of $9.57.

Pyxis Oncology Stock Performance

NASDAQ PYXS traded down $0.09 during mid-day trading on Friday, reaching $4.19. 790,499 shares of the stock were exchanged, compared to its average volume of 633,989. Pyxis Oncology has a 1-year low of $1.35 and a 1-year high of $6.85. The business's fifty day simple moving average is $3.68 and its 200 day simple moving average is $3.66. The stock has a market capitalization of $249.18 million, a PE ratio of -4.10 and a beta of 1.27.

Institutional Investors Weigh In On Pyxis Oncology

A number of large investors have recently made changes to their positions in the company. StemPoint Capital LP purchased a new position in Pyxis Oncology during the first quarter valued at approximately $7,643,000. Ikarian Capital LLC bought a new stake in Pyxis Oncology in the first quarter worth approximately $7,082,000. Vanguard Group Inc. grew its position in Pyxis Oncology by 7.3% in the first quarter. Vanguard Group Inc. now owns 1,401,425 shares of the company's stock worth $5,970,000 after acquiring an additional 94,740 shares in the last quarter. Millennium Management LLC grew its position in Pyxis Oncology by 125.3% in the second quarter. Millennium Management LLC now owns 1,336,908 shares of the company's stock worth $4,425,000 after acquiring an additional 743,499 shares in the last quarter. Finally, Blue Owl Capital Holdings LP bought a new stake in Pyxis Oncology in the second quarter worth approximately $3,462,000. Institutional investors and hedge funds own 39.09% of the company's stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.